SynAct Pharma AB Market Cap ($95.70 Million)
Market Cap & Net Worth: SynAct Pharma AB (SYNACT)
SynAct Pharma AB market cap. SynAct Pharma AB (ST:SYNACT) has a market capitalization of $95.70 Million (Skr889.25 Million) as of November 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #19190 globally and #333 in its home market, demonstrating a -11.78% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SynAct Pharma AB's stock price Skr15.88 by its total outstanding shares 55997997 (56.00 Million). Also see SynAct Pharma AB cash conversion from operations for how efficiently the company converts equity into cash flow.
SynAct Pharma AB Market Cap History (2016–2026)
SynAct Pharma AB market cap history from 2016 to 2026. Data shows growth from $31.41 Million to $95.70 Million (12.58% CAGR). Check current stock price of SynAct Pharma AB for real-time trading data and today's change.
SynAct Pharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SynAct Pharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SynAct Pharma AB (SYNACT) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SYNACT by Market Capitalization
Companies near SynAct Pharma AB in the global market cap rankings as of November 5, 2026. Also see SynAct Pharma AB assets under control for a full breakdown of the balance sheet.
Key companies related to SynAct Pharma AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of SynAct Pharma AB (2016–2026)
Market capitalization of SynAct Pharma AB from 2016 to today. Between 2016 and today, SynAct Pharma AB's market cap moved from $31.41 Million to $ 95.70 Million, with a yearly change of 12.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr95.70 Million | -29.73% |
| 2025 | Skr136.19 Million | +152.09% |
| 2024 | Skr54.03 Million | +1.53% |
| 2023 | Skr53.21 Million | -89.17% |
| 2022 | Skr491.14 Million | -42.77% |
| 2021 | Skr858.14 Million | +221.44% |
| 2020 | Skr266.96 Million | +446.91% |
| 2019 | Skr48.81 Million | +30.29% |
| 2018 | Skr37.47 Million | -34.74% |
| 2017 | Skr57.41 Million | +82.76% |
| 2016 | Skr31.41 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of SynAct Pharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $95.70 Million USD |
| MoneyControl | $95.70 Million USD |
| MarketWatch | $95.70 Million USD |
| marketcap.company | $95.70 Million USD |
| Reuters | $95.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and id… Read more